Next Article in Journal
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
Next Article in Special Issue
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
Previous Article in Journal
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
 
 
Review

Article Versions Notes

Cancers 2020, 12(8), 2236; https://doi.org/10.3390/cancers12082236
Action Date Notes Link
article pdf uploaded. 10 August 2020 15:41 CEST Version of Record https://www.mdpi.com/2072-6694/12/8/2236/pdf-vor
article xml file uploaded 11 August 2020 06:33 CEST Original file -
article xml uploaded. 11 August 2020 06:33 CEST Update -
article pdf uploaded. 11 August 2020 06:33 CEST Updated version of record https://www.mdpi.com/2072-6694/12/8/2236/pdf-vor
article html file updated 11 August 2020 06:35 CEST Original file -
article html file updated 28 August 2020 04:14 CEST Update -
article pdf uploaded. 28 August 2020 07:42 CEST Updated version of record https://www.mdpi.com/2072-6694/12/8/2236/pdf
article xml uploaded. 28 August 2020 07:42 CEST Update -
article xml uploaded. 28 August 2020 07:42 CEST Update https://www.mdpi.com/2072-6694/12/8/2236/xml
article html file updated 28 August 2020 07:43 CEST Update -
article html file updated 22 July 2022 03:05 CEST Update https://www.mdpi.com/2072-6694/12/8/2236/html
Back to TopTop